Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
F2 Ventures is a healthcare investment platform focused on arbitrage opportunities across the biotech sector, targeting innovation at the right stage for maximum impact.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
2/2015 | Chiasma | Series E | 70M |
6/2010 | ProterixBio | Series D | 0 |
11/2007 | ProterixBio | Series C | 20.7M |
3/2020 | ElevateBio | Series B | 170M |
11/2006 | Chiasma | Series C | 44M |
12/2020 | Cullinan Oncology | Series C | 131.2M |
12/2016 | TCR2 | Series A | 44.5M |
9/2022 | 4M Analytics | Series A | 30M |
3/2015 | Clinical Ink | Venture Round | 20M |
3/2018 | TCR2 | Series B | 0 |
9/2021 | Five Sigma | Series A | 0 |
5/2019 | AlloVir | Series B | 120M |
6/2020 | Cullinan Oncology | Series B | 98.5M |
10/2017 | Cullinan Oncology | Series A | 150M |
5/2023 | ReNAgade Therapeutics | Series A | 0 |
2/2005 | ProterixBio | Series B | 3M |
3/2021 | ElevateBio | Series C | 525M |
5/2023 | ElevateBio | Series D | 0 |
7/2022 | AlloVir | Post-IPO Equity | 0 |
9/2005 | Chiasma | Series B | 7.7M |
3/2019 | TriNetX | Series D | 40M |
8/2021 | 4M Analytics | Series A | 11M |
11/2021 | Justt | Series B | 50M |
2/2021 | Orna Therapeutics | Series A | 0 |
12/2015 | iPrice Group | Seed Round | 0 |
5/2023 | ReNAgade Therapeutics | Series A | 0 |
9/2022 | 4M Analytics | Series A | 0 |
7/2022 | AlloVir | Post-IPO Equity | 0 |
11/2021 | Justt | Series B | 0 |
9/2021 | Five Sigma | Series A | 0 |
8/2021 | 4M Analytics | Series A | 0 |
3/2021 | ElevateBio | Series C | 0 |
2/2021 | Orna Therapeutics | Series A | 0 |
12/2020 | Cullinan Oncology | Series C | 0 |
6/2020 | Cullinan Oncology | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|